Key considerations for modelling the long-term costs and benefits of treatments for ANCA-associated vasculitis

CONCLUSIONS: Economic evaluation of new treatments for AAV needs to capture all relevant downstream effects. ESRD is a key driver of cost-effectiveness but is associated with major uncertainty. Future observational studies need to offer sufficient detail to allow for differentiation in event rates across treatment options.PMID:38526008 | DOI:10.55563/clinexprheumatol/eektem
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Authors: Source Type: research